MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, analysis-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative goods, now announced it will provide cannabis concentrate goods in Denmark to two new healthcare cannabis shoppers below two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed goods to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal goods two years ago as element of a 4-year pilot plan. The plan offers individuals with protected solution access and national wellness authorities with patient information that they can use to realize usage and efficacy. According to info complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mostly ladies involving the ages of 42-64) received cannabis-primarily based medicinal goods from 429 prescribing physicians below this plan in 2019.
“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent a further step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare marketplace with new and revolutionary healthcare cannabis focused goods positions us for more development in Europe and adds to MediPharm Labs all-crucial physique of expertise that we are leveraging to improve the design and style of our formulations for individuals and buyers everywhere.”
Below the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil goods that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its shoppers to commence in October 2020, pending regulatory approval by applicable wellness authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured various extremely eye-catching domestic and international provide agreements with higher high-quality partners, now which includes new shoppers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new enterprise wins are a clear and crucial validation of our choice to develop a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs developing profile and reputation. We appear forward to ramping up production below all of these agreements.”
MediPharm Labs Australia received its Superior Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in May possibly 2020, which enables it to sell cannabis APIs and completed goods to nations across the EU, which includes Denmark. The Corporation entered into its very first European white-label cannabis provide agreement that identical month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Industry
Denmark launched its 4-year healthcare cannabis pilot plan on January 1st, 20181. Post-harvest Superior Manufacturing Processes (GMP) is needed for distribution of healthcare cannabis goods in Denmarktwo.
By way of the plan, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 places: discomfort triggered by many sclerosis, discomfort triggered by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive critique of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative goods using a Superior Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an professional, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 principal extraction lines for delivery of pure, trusted and precision -dosed cannabis goods for its shoppers. By way of its wholesale and white label platforms, they formulate, customer-test, procedure, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure